🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The primary objective is to document the safety of tecemotide (L-BLP25) pha...
Status
Completed
Location
Multiple Locations
Start Date
2005-04
Trial ID
NCT00157196
Treatments Being Tested
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (S...
Status
Terminated
Location
Research Site
Start Date
2009-09
Trial ID
NCT00925548
Phase Ib study investigating whether liposome BLP25 mucin-1 (MUC1) peptide-...
Status
Withdrawn
Location
Multiple Locations
Start Date
2001-01
Trial ID
NCT01731587
Treatments Being Tested
Tecemotide (L-BLP25) is believed to induce a Mucinous glycoprotein 1 (MUC1)...
Status
Completed
Location
Please Contact the Merck KGaA Communication Center
Start Date
2008-01
Trial ID
NCT01094548
RATIONALE: Vaccines may help the body build an effective immune response to...
Status
Completed
Location
Veterans Affairs Medical Center - Palo Alto
Start Date
2011-01-17
Trial ID
NCT00828009
Treatments Being Tested
Comparative evaluation of recurrence-free survival (RFS) time and 3 year ov...
Status
Completed
Location
Salzburger Universitätsklinikum, Universitätsklinik für Innere Medizin III
Start Date
2011-08
Trial ID
NCT01462513
The objective of this mechanistic study is to determine the impact of tecem...
Status
Completed
Location
NKI (Nederlands Kanker Instituut)
Start Date
2012-02
Trial ID
NCT01507103
Treatments Being Tested
This is a prospective open label, controlled, randomized study to test the ...
Status
Completed
Location
Please Contact the Merck KGaA Communication Center
Start Date
2000-08
Trial ID
NCT00157209
Treatments Being Tested
The purpose of this study is to determine whether the cancer vaccine tecemo...
Status
Completed
Location
Saint Edward Mercy Medical Center
Start Date
2007-01
Trial ID
NCT00409188
Treatments Being Tested
This is an open-label, common follow-up trial. Subjects who were enrolled i...
Status
Terminated
Location
Merck KGaA Communication Center
Start Date
2012-01
Trial ID
NCT01423760
Treatments Being Tested